drugset
drugset / Trial / NCT03150810

Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors

NCT03150810 ↗

Phase 1 Completed 139 enrolled BeiGene Myriad Genetics, Inc. · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

The primary objective of this study was to determine the safety and tolerability of pamiparib, the maximum tolerated dose (MTD) or maximum administered dose (MAD) for pamiparib combined with TMZ, to select the recommended Phase 2 dose (RP2D) and schedule of pamiparib in combination with TMZ, and to determine the antitumor activity of pamiparib in combination with TMZ.

Timeline

Start
2017-06-28
Primary completion
2023-05-04
Completion
2023-05-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Pamiparib Small molecule 60 mg Oral
Subject Temozolomide Small molecule 20 mg Oral
Subject Temozolomide Small molecule 40 mg Oral
Subject Temozolomide Small molecule 60 mg Oral
Subject Temozolomide Small molecule 80 mg Oral
Subject Temozolomide Small molecule 100 mg Oral
Subject Temozolomide Small molecule 120 mg Oral

Indications

No indication recorded.